New Applications of Clioquinol in the Treatment of Inflammation Disease by Directly Targeting Arginine 335 of NLRP3

Peipei Chen,Yunshu Wang,Huaiping Tang,Chao Zhou,Zhuo Liu,Shenghan Gao,Tingting Wang,Yun Xu,Sen-Lin Ji
DOI: https://doi.org/10.1016/j.jpha.2024.101069
IF: 14.026
2024-01-01
Journal of Pharmaceutical Analysis
Abstract:The NOD-like receptor protein 3 (NLRP3) inflammasome is essential in innate immune-mediated inflammation, with its overactivation implicated in various autoinflammatory, metabolic, and neurodegenerative diseases. Pharmacological inhibition of NLRP3 offers a promising treatment strategy for inflammatory conditions, although no medications targeting the NLRP3 inflammasome are currently available. This study demonstrates that clioquinol (CQ), a clinical drug with chelating properties, effectively inhibits NLRP3 activation, resulting in reduced cytokine secretion and cell pyroptosis in both human and mouse macrophages, with a half maximal inhibitory concentration (IC50) of 0.478 μM. Additionally, CQ mitigates experimental acute peritonitis, gouty arthritis, sepsis, and colitis by lowering serum levels of interleukin-1β (IL-1β), IL-6, and tumour necrosis factor-α (TNF-α). Mechanistically, CQ covalently binds to Arginine 335 (R335) in the NACHT domain, inhibiting NLRP3 inflammasome assembly and blocking the interaction between NLRP3 and its component protein. Collectively, this study identifies CQ as an effective natural NLRP3 inhibitor and a potential therapeutic agent for NLRP3-driven diseases.
What problem does this paper attempt to address?